Zymeworks Inc. (NYSE:ZYME) Director Buys $565,807.86 in Stock

Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc acquired 49,502 shares of Zymeworks stock in a transaction on Thursday, May 15th. The shares were purchased at an average price of $11.43 per share, for a total transaction of $565,807.86. Following the completion of the acquisition, the director now directly owns 17,877,989 shares in the company, valued at $204,345,414.27. This trade represents a 0.28% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, May 19th, Ecor1 Capital, Llc purchased 5,919 shares of Zymeworks stock. The shares were purchased at an average cost of $11.78 per share, for a total transaction of $69,725.82.
• On Wednesday, April 16th, Ecor1 Capital, Llc acquired 73,953 shares of Zymeworks stock. The stock was purchased at an average price of $11.16 per share, with a total value of $825,315.48.
• On Friday, April 4th, Ecor1 Capital, Llc bought 196,438 shares of Zymeworks stock. The shares were acquired at an average price of $11.17 per share, for a total transaction of $2,194,212.46.
• On Wednesday, April 2nd, Ecor1 Capital, Llc purchased 74,360 shares of Zymeworks stock. The stock was acquired at an average price of $11.85 per share, with a total value of $881,166.00.
• On Monday, March 31st, Ecor1 Capital, Llc purchased 4,397 shares of Zymeworks stock. The stock was acquired at an average cost of $11.75 per share, with a total value of $51,664.75.
• On Wednesday, March 26th, Ecor1 Capital, Llc acquired 43,848 shares of Zymeworks stock. The shares were acquired at an average cost of $12.24 per share, for a total transaction of $536,699.52.
• On Monday, March 24th, Ecor1 Capital, Llc bought 22,689 shares of Zymeworks stock. The shares were bought at an average price of $13.08 per share, with a total value of $296,772.12.
• On Friday, March 21st, Ecor1 Capital, Llc purchased 31,033 shares of Zymeworks stock. The stock was bought at an average price of $12.78 per share, for a total transaction of $396,601.74.
• On Wednesday, March 19th, Ecor1 Capital, Llc bought 58,306 shares of Zymeworks stock. The stock was purchased at an average price of $12.64 per share, with a total value of $736,987.84.
• On Monday, March 17th, Ecor1 Capital, Llc acquired 56,277 shares of Zymeworks stock. The shares were bought at an average price of $12.23 per share, for a total transaction of $688,267.71.

Zymeworks Trading Up 0.9%

NYSE:ZYME traded up $0.11 during trading hours on Monday, hitting $11.82. 242,872 shares of the stock were exchanged, compared to its average volume of 598,736. The company has a market cap of $822.40 million, a P/E ratio of -7.88 and a beta of 1.24. The firm’s fifty day moving average price is $11.82 and its 200 day moving average price is $13.38. Zymeworks Inc. has a 52-week low of $8.21 and a 52-week high of $17.70.

Zymeworks (NYSE:ZYME) last announced its earnings results on Thursday, May 8th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.15. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The company had revenue of $27.11 million during the quarter, compared to analyst estimates of $20.65 million. During the same quarter last year, the firm posted ($0.42) earnings per share. Zymeworks’s revenue was up 170.3% compared to the same quarter last year. Equities analysts expect that Zymeworks Inc. will post -1.39 EPS for the current fiscal year.

Analysts Set New Price Targets

ZYME has been the topic of a number of research analyst reports. Citigroup boosted their price objective on shares of Zymeworks from $18.00 to $19.00 and gave the company a “buy” rating in a report on Friday, March 7th. Lifesci Capital started coverage on shares of Zymeworks in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $30.00 price objective on the stock. Finally, HC Wainwright raised their target price on shares of Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a report on Monday, March 10th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Hedge Funds Weigh In On Zymeworks

A number of institutional investors and hedge funds have recently modified their holdings of the company. Nuveen Asset Management LLC boosted its holdings in Zymeworks by 0.4% in the fourth quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company’s stock valued at $3,031,000 after purchasing an additional 886 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Zymeworks by 6.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,605 shares of the company’s stock valued at $214,000 after buying an additional 940 shares in the last quarter. Janney Montgomery Scott LLC grew its position in shares of Zymeworks by 12.7% in the 1st quarter. Janney Montgomery Scott LLC now owns 11,567 shares of the company’s stock valued at $138,000 after buying an additional 1,300 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Zymeworks by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,385 shares of the company’s stock worth $386,000 after acquiring an additional 1,427 shares in the last quarter. Finally, Picton Mahoney Asset Management lifted its position in Zymeworks by 0.7% in the first quarter. Picton Mahoney Asset Management now owns 208,029 shares of the company’s stock valued at $2,477,000 after acquiring an additional 1,460 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.